Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Viruses ; 9(11)2017 11 15.
Article in English | MEDLINE | ID: mdl-29140260

ABSTRACT

The orthopoxviruses (OPV) comprise several emerging viruses with great importance to human and veterinary medicine, including vaccinia virus (VACV), which causes outbreaks of bovine vaccinia (BV) in South America. Historically, VACV is the most comprehensively studied virus, however, its origin and natural hosts remain unknown. VACV was the primary component of the smallpox vaccine, largely used during the smallpox eradication campaign. After smallpox was declared eradicated, the vaccination that conferred immunity to OPV was discontinued, favoring a new contingent of susceptible individuals to OPV. VACV infections occur naturally after direct contact with infected dairy cattle, in recently vaccinated individuals, or through alternative routes of exposure. In Brazil, VACV outbreaks are frequently reported in rural areas, affecting mainly farm animals and humans. Recent studies have shown the role of wildlife in the VACV transmission chain, exploring the role of wild rodents as reservoirs that facilitate VACV spread throughout rural areas. Furthermore, VACV circulation in urban environments and the significance of this with respect to public health, have also been explored. In this review, we discuss the history, epidemiological, ecological and clinical aspects of natural VACV infections in Brazil, also highlighting alternative routes of VACV transmission, the factors involved in susceptibility to infection, and the natural history of the disease in humans and animals, and the potential for dissemination to urban environments.


Subject(s)
Communicable Diseases, Emerging/epidemiology , Public Health , Vaccinia virus , Vaccinia/epidemiology , Zoonoses/epidemiology , Animals , Brazil , Communicable Diseases, Emerging/economics , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/virology , Dairying/economics , Humans , Vaccination/economics , Vaccinia/economics , Vaccinia/virology , Zoonoses/economics , Zoonoses/prevention & control , Zoonoses/virology
2.
Arch Virol ; 160(11): 2703-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26239343

ABSTRACT

Vaccinia virus (VACV), the etiological agent of bovine vaccinia (BV), is widespread in Brazil and present in most of the milk-producing regions. We conducted a horizontal study of BV in Bahia, a state of Brazil in which the production of milk is increasing. During 2011, human and bovine clinical samples were collected during outbreaks for BV diagnosis, virus isolation and molecular analysis. We collected data for epidemiological inferences. Vaccinia virus was detected in 87.7% of the analyzed outbreaks, highlighting the effective circulation of VACV in Bahia. The molecular data showed the spreading of group 1 Brazilian VACV to Bahia. We observed a seasonal profile of BV, with its peak in the drier and cooler season. Manual milking was observed in 96 % of the visited properties, showing its importance to viral spread in herds. Under-notification of BV, ineffective animal trade surveillance, and bad milking practices have contributed to the spread of VACV in Brazil.


Subject(s)
Cattle Diseases/virology , Phylogeny , Vaccinia virus/classification , Vaccinia virus/isolation & purification , Vaccinia/veterinary , Vaccinia/virology , Animals , Brazil , Cattle , Cattle Diseases/economics , Cattle Diseases/epidemiology , Cattle Diseases/transmission , Disease Outbreaks/economics , Humans , Vaccinia/economics , Vaccinia/epidemiology , Vaccinia/transmission , Vaccinia virus/genetics , Zoonoses/economics , Zoonoses/epidemiology , Zoonoses/transmission , Zoonoses/virology
3.
Fed Regist ; 68(166): 51492-9, 2003 Aug 27.
Article in English | MEDLINE | ID: mdl-12952013

ABSTRACT

The Smallpox Emergency Personnel Protection Act of 2003 (SEPPA), Public Law 108-20, 117 Stat. 638, authorized the Secretary of Health and Human Services (the Secretary), through the establishment of the Smallpox Vaccine Injury Compensation Program (the Program), to provide benefits and/or compensation to certain persons who have sustained injuries as a result of the administration of smallpox covered countermeasures (including the smallpox vaccine) or as a result of vaccinia contracted through accidental vaccinia inoculations. The SEPPA directed the Secretary to establish, by interim final rule, a table identifying adverse effects (including injuries, disabilities, conditions, and deaths) that shall be presumed to result from the administration of or exposure to the smallpox vaccine, and the time interval in which the first symptom or manifestation of each listed injury must manifest in order for such presumption to apply. As mandated by law, the Secretary is establishing such a Smallpox (Vaccinia) Vaccine Injury Table (the Table) through this interim final rule. The Secretary is also establishing a set of Table Definitions and Requirements, which define the terms and conditions included on the Table and are to be read in conjunction with the Table. The Secretary is seeking public comment on the Table established through this interim final rule. At a later date, the Secretary will publish a companion final rule setting forth the administrative implementation of the Program. The public will then be afforded an additional opportunity to comment on the procedures set forth therein.


Subject(s)
Compensation and Redress/legislation & jurisprudence , Smallpox Vaccine/adverse effects , Vaccinia/economics , Eligibility Determination/legislation & jurisprudence , Humans , Smallpox Vaccine/economics , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...